Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

标题
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 120, Issue 9, Pages 896-902
出版商
Springer Science and Business Media LLC
发表日期
2019-04-04
DOI
10.1038/s41416-019-0443-4

向作者/读者发起求助以获取更多资源

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search